

1 **Characterization of the Cellular Immune Response to Group B Streptococcal Vaginal Colonization**

2
3 **Brady L. Spencer**^{a†*}, Dustin T. Nguyen^a, Stephanie M. Marroquin^a, Laurent Gapin^a, Rebecca L. O'Brien^b,
4 Kelly S. Doran^{a*}

5
6 ^aUniversity of Colorado-Anschutz, Department of Immunology & Microbiology, Aurora, CO, USA

7 ^bNational Jewish Health, Department of Biomedical Research, Denver, CO, USA

8 [†]Present address: University of Virginia, Department of Microbiology, Immunology, and Cancer Biology,
9 Charlottesville, VA, USA

10
11
12 **Short Title:** Cellular FGT immune responses to GBS

13
14 ***Corresponding Authors:**

15 Brady L. Spencer
16 brady.spencer@virginia.edu

17
18 Kelly S. Doran
19 Kelly.doran@cuanschutz.edu

20
21
22 **Keywords:** vaginal colonization, mucosal immunity, *Streptococcus agalactiae*, group B *Streptococcus*

23

24

25

26

27

28

29

30

31

32

33

34 **Abstract**

35 **Introduction:** Group B *Streptococcus* (GBS) asymptomatic colonizes the female genital tract (FGT) but can
36 contribute to adverse pregnancy outcomes including pre-term birth, chorioamnionitis, and neonatal infection.
37 We previously observed that GBS elicits FGT cytokine responses, including IL-17, during murine vaginal
38 colonization; yet the anti-GBS cellular immune response during colonization remained unknown. We
39 hypothesized that GBS may induce cellular immunity, resulting in FGT clearance.

40
41 **Methods:** Herein, we utilize depleting antibodies and knockout mice and performed flow cytometry to
42 investigate cellular immune responses during GBS colonization.

43
44 **Results:** We found that neutrophils (effectors of the IL-17 response) are important for GBS mucosal control
45 as neutrophil depletion promoted increased GBS burdens in FGT tissues. Flow cytometric analysis of immune
46 populations in the vagina, cervix, and uterus revealed, however, that GBS colonization did not induce a
47 marked increase in FGT CD45⁺ immune cells. We also found that that V γ 6⁺ $\gamma\delta$ T cells comprise a primary
48 source of FGT IL-17. Finally, using knockout mice, we observed that IL-17-producing $\gamma\delta$ T cells are important
49 for the control of GBS in the FGT during murine colonization.

50
51 **Conclusions:** Taken together, this work characterizes FGT cellular immunity and suggests that GBS
52 colonization does not elicit a significant immune response, which may be a bacterial directed adaptive
53 outcome. However, certain FGT immune cells, such as neutrophils and $\gamma\delta$ T cells, contribute to host defense
54 and control of GBS colonization.

55
56
57
58
59
60
61
62
63

64 Introduction

65 Group B *Streptococcus* (GBS), or *Streptococcus agalactiae*, is a Gram-positive, β -hemolytic bacterium that
66 asymptotically colonizes the gastrointestinal tract and the female genital tract (FGT) of 10-30% of healthy
67 adults in the United States [1]. GBS can cause infection in immunocompromised adults [2], and it presents
68 problems in pregnancy as ascension of vaginally colonizing GBS to the uterus can cause complications
69 including chorioamnionitis and preterm births [3, 4]. Further, GBS neonatal early-onset disease (EOD) results
70 from maternal transmission to the neonate *in utero* or during birth, presenting within 7 days after birth as
71 pneumonia, bacteremia, and in severe cases, meningitis [5]. GBS is a leading cause of neonatal infection
72 and causes 2-3% mortality of term newborns and up to 30% of preterm newborns who develop GBS disease
73 [6-8]. Despite this, no GBS vaccine is currently available, and antibiotic prophylaxis is the primary treatment
74 for pregnant women testing positive for GBS recto-vaginal swab at 37 weeks [4]. Even with this intervention,
75 GBS remains a global health issue as the primary risk factor for neonatal EOD is maternal vaginal colonization
76 with GBS [4]. Thus, understanding GBS-host interactions in the mucosal environment of the FGT is needed
77 to develop new therapies.

78
79 Similar to other mucosal barriers, the FGT contains numerous defenses to prevent colonization and invasion
80 of pathogens, such as physical epithelial and mucus barriers, chemical defenses (antimicrobial peptides, low
81 pH), as well as the vaginal microbiota [9, 10]. Soluble and cellular immune responses within the FGT can
82 also be initiated to control infection [11, 12]. While immune responses to viral and fungal pathogens have
83 been characterized in the FGT, less work has been done to characterize cellular immune responses to
84 vaginal pathobionts and opportunistic pathogens in this niche.

85
86 As an opportunistic pathogen, GBS encodes numerous virulence factors that allow it to persist in the mucosa
87 and ascend to the uterus despite these host defenses, including adhesins and invasins (BspC, Srr proteins,
88 pili) [13-15], a β -hemolysin/cytolysin [16-18], a hyaluronidase [19], capsular polysaccharide [20], and a type
89 VII secretion system [21, 22]. While these factors have individually been shown to promote GBS colonization
90 and/or ascending infection, previous work from our laboratory found that GBS clinical isolates exhibit a range
91 of murine vaginal persistence over time [23] and a single GBS determinant responsible for this differential
92 clearance has yet to be identified. Previous work from our laboratory and others have also profiled cytokine
93 responses in response to various GBS isolates, assessing both *in vitro* cytokine analysis from GBS infection

94 of vaginal epithelium as well as cytokine induction within GBS-colonized FGT tissue homogenates, with some
95 isolates eliciting more cytokine induction than others [23, 24]. Based on this, we hypothesized that GBS
96 strains may elicit cellular immune responses during colonization and ascension to the uterus, which result in
97 their clearance from the FGT. In this study, we profiled the cellular immune responses to persistent-colonizing
98 serotype V GBS isolate CJB111, and to serotype III GBS isolate COH1 in the vagina, cervix, and uterus, and
99 show the importance of specific immune populations in controlling GBS during FGT colonization.

100 101 **Methods**

102 Mice

103 CD-1 (outbred Swiss) mice were obtained from Charles River Laboratories. C57BL/6J mice were originally
104 obtained from Jackson Laboratory and bred at National Jewish Health (Denver, CO) and then University of
105 Colorado-Anschutz (Aurora, CO). TCR-V γ 4⁻/V γ 6⁻ mice in the C57BL/6J genetic background were originally
106 derived from TCR-V γ 4⁻/V γ 6⁻ mouse line generated by Dr. Koichi Ikuta (Kyoto University, Kyoto, Japan).

107 108 Bacterial strains and growth

109 GBS isolates COH1 [25] and CJB111 [26] were grown statically in Todd-Hewitt Broth (THB; Research
110 Products International, RPI Catalog# T47500) at 37°C. For vaginal colonization experiments, bacteria were
111 grown to mid-logarithmic phase (OD₆₀₀ of approximately 0.4) and normalized in PBS to 1x 10⁹ CFU/mL.

112 113 Neutrophil depletion in mice

114 Murine neutrophil depletion protocols were adapted from [27]. Depleting α -Ly6G (BioXCell, clone 18A) and
115 IgG2a isotype control (BioXCell, clone 2A3) antibodies were diluted in buffered reagent diluent to a
116 concentration of 2 mg/mL and animals were intraperitoneally injected with 100 μ L (dose of 200 μ g) the day
117 prior to vaginal bacterial inoculation. A second dose was administered intraperitoneally three days later at
118 day 2 post-GBS inoculation.

119 120 Murine model of vaginal colonization

121 GBS vaginal colonization and tissue invasion were assessed using a previously described murine model of
122 vaginal persistence and ascending infection [28]. 8-week-old female CD-1 outbred mice or 8-16-week-old
123 C57BL/6J and TCR-V γ 4⁻/V γ 6⁻ mice in the C57BL/6J genetic background were synced with β -estradiol at

124 day -1 and inoculated with 1×10^7 GBS in 10 μ L of phosphate buffered saline (PBS) on day 0. Post-
125 inoculation, mice were vaginally lavaged with PBS, and the samples were serially diluted and plated for CFU
126 quantification to determine bacterial persistence on differential and selective GBS CHROMagar (catalog#
127 SB282(B)). At experimental time points, mice were euthanized, and FGT tissues were harvested. In
128 experiments using knockout mice or neutrophil depletion, tissues were homogenized and then serially diluted
129 and plated on CHROMagar for CFU enumeration. In experiments assessing immune responses, tissues were
130 processed as described below, serially diluted, and plated on CHROMagar for CFU enumeration. Bacterial
131 counts were normalized to tissue weight.

133 Dissociation of FGT tissues for flow cytometry

134 To evaluate cellular immune responses in the FGT, following euthanasia, mice were perfused with PBS and
135 heparin through left ventricle cardiac puncture. Vaginal, cervical, and uterine tissue were obtained from
136 terminal harvest, minced with a razor blade, and suspended in 2.4 mL RPMI 1640 medium (RPMI; Corning).
137 Digestion enzymes were obtained from Miltenyi Biotec Multi Tissue Dissociation Kit 1 and resuspended
138 according to manufacturer instructions. 100 μ L Enzyme D, 50 μ L Enzyme R, 12.5 μ L Enzyme A were added
139 to each tissue sample in RPMI. Tissues were mechanically dissociated using gentleMACS™ C Tubes
140 (Miltenyi Biotec; protocol Multi H). Tissues suspensions were placed in a rocking shaker at 37°C for 1 hour,
141 with an additional 30 second mechanical dissociation half-way through the incubation. The digestion mixture
142 was strained through a 70 μ m filter, and the single cells were spun down at 300 x g for 5 minutes and washed
143 with RPMI. The cell pellet was resuspended in Ammonium-Chloride-Potassium red blood cell lysis buffer
144 (150 mM NH_4Cl , 10 mM KHCO_3 , 0.1 mM Na_2EDTA) for 1 minute at room temperature and diluted in RPMI.
145 Following centrifugation, the cell pellet was resuspended in MACS staining buffer (1X PBS, 2 mM EDTA,
146 0.5% BSA) to generate single cell suspensions.

148 Antibody staining of single cell suspension for flow cytometry analysis

149 Fixable Viability Dye eFluor™ 506 (ThermoFisher; 1:800 dilution) in PBS was added to single cell
150 suspensions and allowed to incubate for 15 minutes at room temperature. The innate flow cytometric panel
151 was adapted from [29] and a T cell flow cytometric panel was developed in the present study. Conjugated
152 antibodies listed in **Supplemental Table 1** were then added to single cell suspensions along with anti-mouse
153 CD16/32 (ThermoFisher, clone 2.4G2) to block mouse Fc receptors for 30 minutes at room temperature.

154 Stained cells were then washed and prepared for fixation and permeabilization using Foxp3/Transcription
155 Factor Staining Buffer Set (eBioscience) according to the manufacturer's protocol. Prior to running samples
156 on the flow cytometer, conjugated antibodies for intracellular targets were added to cells in permeabilization
157 buffer for 30 minutes at room temperature. Cells were washed and resuspended and analyzed on the
158 CytoFlex (Beckman Coulter) and LSRFortessa (BD Biosciences) flow cytometers. Data were analyzed with
159 BD FlowJo software version 10.10.0. Single-stained beads (Versacomp Antibody Capture Bead Kit; Beckman
160 Coulter) were used as compensation controls.

161
162 A detailed gating strategy was established based on single stain and fluorescence minus one controls (**SFig**
163 **2a, b**). In this study, we found that cells from a subset of mice were not recognized by our anti-MHCII antibody
164 (clone M5/114 15.2), which reacts with a polymorphic determinant shared by the I-A^b, I-A^d, I-A^q, I-E^d, and I-
165 E^k MHC class II alloantigens, but does not react with I-A^f, I-A^k, or I-A^s MHC class II alloantigens. We expect
166 that these mice carry other MHC class II haplotypes, but this would need to be experimentally shown.
167 Because MHCII staining impacts our innate gating strategy, mice exhibiting negative MHCII staining were
168 excluded from our innate immune analysis. We similarly observed that cells from some CD-1 outbred mice
169 did not react with our anti-Ly6C antibody, and the reason for this remains unclear. Because of this we did not
170 use Ly6C expression to define populations within our gating strategy.

171 172 Stimulation assays

173 Single cell suspensions of FGT tissues were prepared for flow cytometry as previously stated. The final pellet
174 was resuspended in 2 mL of cell stimulation media: RPMI with L-glutamine, supplemented with 10% FBS,
175 1X non-essential amino acids, 1mM sodium pyruvate, 10 mM HEPES (Gibco). Cells were stimulated with 1X
176 eBioscience Cell Stimulation Cocktail (Thermo, 00-4970-93) containing PMA and ionomycin for one hour at
177 37°C. GolgiStop™ Protein Transport Inhibitor (BD Biosciences, 554724) was added at a 6.67uL/mL media
178 concentration at this time and cells were incubated for an additional 4 hours at 37°C, for a total stimulation
179 time of 5 hours. Cells were washed twice with MACS staining buffer and flow cytometric staining progress as
180 described above with the addition of IL-17A-PE-Cy7 (Invitrogen, [eBio1787], 25-7177-80) antibody staining
181 following fixation/permeabilization. In some assays, a PE-conjugated antibody to the Vγ6 TCR was included
182 (Clone 1C10-1F7, BD Pharmingen, Catalog # 570217) to specifically identify Vγ6+ γδ T cells [30].

184 Statistical Analysis

185 Data were analyzed using PRISM9 (GraphPad Software). Data are depicted as mean \pm SEM or median
186 where indicated. P-values are denoted by *(P<0.05), **(P<0.01), ***(P<0.001), and ****(P<0.0001).

187

188 **Results**

189 **Neutrophils control GBS burdens during FGT colonization**

190 Previous work from our laboratory identified elevated IL-17 levels during CJB111 FGT colonization and found
191 that proportions of IL-17⁺ immune populations were higher in mice that had cleared GBS [23]. However, the
192 downstream implications of IL-17 signaling were not investigated. IL-17 family cytokines are known to
193 stimulate production of chemokines such as G-CSF and IL-8, resulting in the recruitment of neutrophils [31].
194 In this study, to determine if neutrophils contribute to the control of GBS FGT colonization and uterine
195 ascension, we performed systemic neutrophil depletion using an anti-Ly6G antibody. CD-1 outbred mice
196 were administered IP injections of anti-Ly6G or an isotype control IgG2a the day prior to GBS inoculation and
197 two days post-GBS inoculation as shown in **Figure 1a** and neutrophil depletion was confirmed in FGT tissues
198 at day 4 by flow cytometry (**SFig. 1**). To determine the functional impact of neutrophils on bacterial burden
199 during colonization, we assessed GBS CFU in FGT tissues of mice in the presence or absence of neutrophil
200 depletion at 4 days post-inoculation. We found that neutrophil-depleted mice exhibited higher burdens of
201 GBS in the vagina, cervix, and uterus compared to non-depleted isotype-injected controls (**Fig. 1b-d**). This
202 was also observed in the vagina and uterus using another GBS strain, COH1 (**Fig. 1e-g**). These data suggest
203 that neutrophils may help to control GBS burdens during colonization.

204

205 **Assessment of FGT immune populations during GBS colonization by flow cytometry**

206 We next sought to evaluate changes in immune populations within FGT tissues during colonization using a
207 previously published innate panel as well as a T cell panel we developed here to assess immune cells in FGT
208 tissues (**SFig. 2a, b**). This innate panel allows for identification of various populations including neutrophils
209 (CD11b⁺ Ly6G⁺), SSClo/MHCII⁻ (including NK cells and monocytes), dendritic cells (CD11c⁺ MHCII⁺),
210 macrophages (CD11b⁺ F4/80⁺), as well as a CD24⁺ population (likely including eosinophils; CD11b⁺ CD24⁺
211 Ly6G⁻ F4/80⁻) [29]. Additionally, the T cell panel allows for identification of $\gamma\delta$ T cells, and TCR β ⁺ T cells,
212 including CD4⁺ and CD8⁺ T cells. To identify host cellular responses to GBS in the FGT, we vaginally
213 inoculated CD-1 outbred mice with PBS or GBS isolate CJB111 and dissociated vaginal, cervical, and uterine

214 tissues at 1, 4, 7, 14, and 28 days after GBS inoculation for flow cytometric analysis. We did not observe a
215 significant difference in numbers of CD45⁺ immune cells (as a proportion of total single cells) in CJB111-
216 colonized animals when compared to naïve animals over a time course of colonization (**Fig. 2a**). Similar
217 results were observed with another GBS isolate, COH1 (**SFig. 3a**) [23].

218
219 To evaluate the dynamics of the cellular immune response, we next examined specific cell innate and T cell
220 populations over a time course of GBS colonization. We did not observe a significant increase in neutrophils
221 in FGT tissues during GBS colonization compared to mock-colonized animals, although there was a slight
222 but not significant trend for increased neutrophils in tissues of GBS-colonized mice at early timepoints (**Fig.**
223 **2b, c**). We similarly observed no significant differences in total number of neutrophils following colonization
224 with another GBS isolate, COH1 (**SFig. 3b, c**). Upon investigation of other innate and T cell populations, we
225 consistently found no major changes in immune population proportions at the time points examined over the
226 course of GBS colonization (**SFig. 4-5**). In fact, in some cases, such as for CD4⁺ and DN TCR β ⁺ T cell
227 populations, GBS colonization appeared to slightly (but not significantly) lower immune cell percentages
228 (**SFig. 5**). These data suggest that GBS may not dramatically alter the immune landscape of the FGT during
229 cervicovaginal colonization of nonpregnant mice.

231 **Importance of IL-17⁺ immune populations to GBS clearance in the FGT**

232 T cells are a major source of IL-17 [32, 33] and, in C57BL/6 mice it is known that $\gamma\delta$ T cells are a primary
233 source of IL-17 in the FGT [34]. To evaluate cellular sources of IL-17 in the FGT of CD-1 outbred mice, we
234 harvested FGT tissues, generated single cell suspensions, and stimulated cells with PMA/ionomycin to elicit
235 cytokine production (**Fig 3a**). Following stimulation, we found that $\gamma\delta$ T cells also comprise the majority of
236 FGT IL-17⁺ cells in CD-1 mice (**Fig 3b, c**). $\gamma\delta$ T cells are among the first immune cells to take residence in
237 the murine FGT during development (69). These FGT-resident $\gamma\delta$ T cells express a V γ 6 T cell receptor (TCR)
238 and are known to be IL-17 producing and to promote clearing of bacterial infections (70-72). To evaluate if
239 FGT V γ 6⁺ $\gamma\delta$ T cells are included in our observed IL-17 $\gamma\delta$ T cell population, we repeated stimulation assays
240 and concurrently stained for V γ 6. Indeed, we found that the majority of IL-17-producing $\gamma\delta$ T cells in the FGT
241 express the V γ 6 TCR (**Fig 3d**). Based on these results, we next hypothesized that resident V γ 6⁺ IL-17
242 producing $\gamma\delta$ T cells may be important for controlling GBS burdens during vaginal colonization and ascension
243 to the uterus. To investigate this, we utilized a previously characterized mouse line that lacks IL-17-producing

244 V γ 4 and V γ 6 $\gamma\delta$ T cells [35, 36]. Upon colonization of WT C57BL/6J or V γ 4^{-/-}6^{-/-} mice with GBS, we found that
245 GBS persisted longer in the vaginal lumen (**Fig 4a**), and within vaginal, cervical, and uterine tissue in mice
246 lacking V γ 4⁺ or V γ 6⁺ $\gamma\delta$ T cells (**Fig 4b-d**). These data indicate that IL-17-producing $\gamma\delta$ T cells may be
247 important for control of GBS colonization and subsequent infection.

249 Discussion

250 In this work, we have identified neutrophils as contributors to control of GBS during FGT colonization of non-
251 pregnant CD-1 outbred mice. We further profiled the immune landscape of the FGT during GBS colonization
252 and found that immune cell populations, including neutrophils, largely do not change over a time-course of
253 colonization using two unique GBS isolates, with slight but not significantly increased trends observed in
254 neutrophil populations at some early timepoints. We hypothesize that this may reflect an evolutionary
255 adaptation by GBS to promote colonization in the FGT and to evade host clearance. IL-17 has been
256 associated with GBS clearance previously and, in this study, we identified $\gamma\delta$ T cells as major producers of
257 IL-17 in the FGT of CD-1 outbred mice. We further show evidence for a contribution of IL-17-producing $\gamma\delta$ T
258 cells in controlling GBS during vaginal colonization and ascension to the uterus. These data highlight the
259 commensal status of GBS in the FGT but also indicate that bacterial control by certain immune populations
260 is possible and may be needed to keep colonization asymptomatic and in check.

262 Our flow cytometric panels enabled detection of a variety of innate populations, including neutrophils,
263 SSClo/MHCII⁻ cells (including monocytes and NK cells), dendritic cells, and macrophages. We further
264 assessed T cell populations, including $\gamma\delta$ T cells, and TCR β ⁺ T cells (CD4⁺, CD8⁺, and double-negative (DN)).
265 However, due to limitations in numbers of fluorophores in our conventional flow cytometric panels, we were
266 not able to evaluate all immune populations. For example, while markers for mast cells were not included in
267 our panel, mast cells have been shown to promote clearance of hyperpigmented GBS from the female genital
268 tract [37]. Further, previous studies have shown increased GBS vaginal persistence in B-cell-deficient mice
269 or those lacking neonatal Fc-receptor, indicating that mucosal B cells and humoral immunity are important
270 for GBS vaginal clearance [38]. It is possible that altered B cell numbers may contribute to the greater
271 susceptibility of the V γ 4/6^{-/-} mice, as it has been previously shown that they have reduced numbers of
272 peripheral B cells [39]. Our study did not assess B cell or antibody responses to GBS over a time-course of
273 colonization, but this would be of interest in the future, particularly in the context of recurrent colonization.

274

275 While our study is the first to our knowledge to profile innate and T cell responses over a comprehensive time
276 course of GBS vaginal colonization, other previous studies have also investigated immune responses to GBS
277 in the FGT. For example, in a murine model of chronic GBS FGT colonization, lymphocyte and PMN cell
278 infiltration were observed at the vaginal mucosal surface [17]. Interestingly, while cytokine responses were
279 observed in vaginal tissues, this study found that changes in neutrophil and macrophage numbers were not
280 observed within the submucosa by flow cytometry and GBS was not readily cleared from the FGT at these
281 timepoints. Our laboratory has previously identified neutrophils in FGT tissue and has detected
282 myeloperoxidase (MPO, used as an indicator of neutrophil recruitment) during colonization by
283 hyperpigmented GBS [16]. In the present study, we also observed neutrophils in FGT tissues during GBS
284 colonization by flow cytometry; however, we only observed slight, non-significant GBS-dependent increases
285 in neutrophil numbers in the tissues at some early timepoints. Interestingly, induction of cytokine responses
286 in the absence of robust immune infiltrate was also observed in murine model of GBS urinary tract infection,
287 indicating GBS may broadly avoid immune infiltration during mucosal colonization/infection [40]. It is possible
288 that while we did not observe differences in immune cell numbers, there may be functional or phenotypic
289 immune changes during GBS colonization that we did not capture with our flow cytometric panels. Indeed,
290 depletion experiments in this study indicated that FGT neutrophils may be important for controlling GBS
291 colonization and uterine ascension. This was similarly reported in a recent study in pregnant mice, which
292 observed increased GBS burden upon neutrophil depletion in the vagina and placenta (although not the
293 cervix and uterus) [41].

294

295 Our results suggest that a steady immune state may facilitate persistent GBS colonization in the
296 cervicovaginal tract over time. In a longitudinal study tracking women's colonization status, 60% of the GBS-
297 colonized cohort were persistently colonized throughout their pregnancies, often with the same isolate of
298 GBS, with some considered "chronically" colonized since they tested GBS-positive at each sampling over the
299 21 month study period [42]. Further, in a study assessing GBS colonization pre- and post- pregnancy (~8-10
300 weeks apart), almost 60% of women were colonized at both timepoints, and in 82% of these women the
301 sequence type/serotype of the isolate did not change [43]. Further, several studies have observed that more
302 than one third of women had recurrent GBS colonization in a subsequent pregnancy [44]. One interpretation
303 of these data is that mounting of a successful, clearing anti-GBS immune response may be inconsistent with

304 the ability of GBS to colonize long-term and recurrently. Collectively, these data are consistent with GBS
305 being a persistent, albeit sometimes intermittent, commensal within the cervicovaginal tract and our results
306 may help to explain the long-term and recurrent nature of GBS colonization in women. In contrast, during
307 pregnancy, immune infiltration is characteristic of chorioamnionitis [45], and studies have modeled this
308 inflammation and infiltration within gestational tissues during GBS infection of pregnant mice that mimics
309 human disease [18, 46, 47]. While GBS has been shown to induce neutrophil and placental macrophage
310 extracellular traps (NETs, METs) *ex vivo* [46, 48] and results in exacerbated inflammation in gestational
311 membranes, increasing reports suggest that GBS may also thwart host defense, including subversion of
312 killing by NETS [18, 49-51]. A recent study also showed that maternal immunity may be dampened during
313 gestational diabetes, thereby promoting GBS perinatal infection [41]. It is possible that GBS may elicit
314 increased immune infiltration at the maternofetal interface compared to the cervicovaginal tract and that
315 alterations in hormones during pregnancy and/or in maternal metabolism in diabetes may further change
316 FGT immune responses.

317
318 IL-17 responses constitute host defense against extracellular bacteria. Briefly, IL-23 production by epithelium
319 or innate immune cells following pathogen detection stimulates mucosal T cells to produce IL-17. This
320 induces epithelial upregulation of antimicrobial peptides as well as chemokines, which recruits neutrophils to
321 the site of infection [52]. Previous work from our laboratory found that IL-17 levels are increased in vaginal
322 tissue of GBS-colonized mice compared to PBS-colonized controls and that IL-17⁺ populations were
323 associated with mice that had cleared GBS colonization [23]. IL-17 is produced by a variety of cell types
324 including $\alpha\beta$ T cells (Th17) [53], $\gamma\delta$ T cells [54], CD8 T cells [55], mucosal associated invariant T (MAIT) cells
325 [56], invariant Natural Killer T (iNKT) cells [57-59], as well as some innate populations, including ILC3s [60],
326 alveolar macrophages [61] and neutrophils [62]. $\gamma\delta$ T cells expressing the V γ 6/V δ 1-invariant TCR [37]
327 represent one of the first T cell types to colonize mucosal sites early in development [36] and are primary
328 early producers of IL-17 in many disease and infection settings, characterized by their quick induction by IL-
329 23 (independent of TCR stimulation) and importance in controlling infection [33, 54]. Similar to previous
330 studies [63, 64], we show here that naïve FGT $\gamma\delta$ T cells from CD-1 outbred mice are capable of producing
331 IL-17 following stimulation. While we did not observe an expansion of total $\gamma\delta$ T-cells in the FGT upon GBS
332 colonization, our primary T cell panel did not include examination of those expressing V γ 6. Therefore, we
333 were unable to determine whether numbers of V γ 6 $\gamma\delta$ T cells specifically changed during GBS vaginal

334 colonization. Despite this, IL-17 producing $\gamma\delta$ T cells appear to be important for controlling GBS colonization
335 as evidenced by increased GBS burdens in FGT tissues of $V\gamma 4/6^{-/-}$ mice compared to C57BL/6J WT mice.
336 Future work will assess the contribution of IL-17 from other sources, such as Th17, MAIT, and iNKT cells and
337 its impact on GBS vaginal colonization. These additional innate T cell populations may be of particular
338 relevance as GBS encodes riboflavin biosynthesis machinery and therefore likely produces the 5-OP-RU
339 ligand recognized by MAIT cells [65] and as iNKT cells have been previously shown to recognize group B
340 streptococcal diacylglycerol-containing glycolipids [66] and to mediate immune responses upon immunization
341 with a synthetic non-toxic derivative of the GBS toxin [67].

342
343 Altogether, this work represents a step towards understanding the complex interplay between GBS and the
344 host immune systems during vaginal colonization and persistence in the FGT. GBS employs many immune
345 evasive techniques, nicely reviewed elsewhere [68, 69], including the expression of the the β -
346 hemolysin/cytolysin, a hemolytic pigment that promotes killing of a variety of immune cells [70, 71, 49, 72].
347 Recently, our laboratory has also identified a type VII secretion system in GBS that promotes vaginal
348 persistence [22], and our current work is investigating a role for the T7SS effectors in modulating immune
349 responses to GBS in the FGT. Understanding the host response to GBS during FGT colonization may
350 facilitate new methods to limit GBS persistence in this niche as well as vertical transmission during
351 pregnancy.

352 353 **Statements**

354 **Acknowledgement (optional)**

355 We acknowledge Drs. Harsha Krovi, and Henri Jupille, in technical development and consulting on these
356 protocols and flow cytometric panels. We would also like to thank Jeremy Rahkola for his assistance with
357 optimization of the flow cytometric panel and analysis and Arianne Crossen for technical assistance.

358 359 **Statement of Ethics**

360 Animal experiments were performed using accepted veterinary standards as approved by the Institutional
361 Animal Care and Use Committee at University of Colorado-Anschutz protocol #00316. The University of
362 Colorado-Anschutz is AAALAC accredited, and their facilities meet and adhere to the standards in the “Guide
363 for the Care and Use of Laboratory Animals”.

364

365 **Conflict of Interest Statement**

366 The authors have no conflicts of interest to declare.

367

368 **Funding Sources**

369 Funding for this work was provided by NIH/NIAID T32 AI007405 and NIH/NIAID F32 AI143203 to BLS,
370 NIH/NIAID F32 AI186285 to SMM, and NIH/NIAID R01 AI153332 and NIH/NINDS R01 NS116716 to KSD.

371

372 **Author Contributions**

373 Brady Spencer: Conceptualization, Investigation, Formal Analysis, Methodology, Visualization, Writing—
374 Original draft and Review/Editing. Dustin Nguyen: Investigation, Formal Analysis, Methodology, Visualization,
375 Writing—Original draft and Review/Editing. Stephanie Marroquin: Investigation, Review/Editing. Laurent
376 Gapin: Resources, Methodology, Writing—Review/Editing. Rebecca O'Brien: Resources, Methodology,
377 Writing—Review/Editing. Kelly Doran: Conceptualization, Funding Acquisition, Supervision, Writing—
378 Review/Editing.

379

380 **Data Availability Statement**

381 The data that support the findings of this study are available from the corresponding author upon reasonable
382 request.

383

384 **Figure Legends**

385 **Figure 1. Systemic depletion of neutrophils results in increased GBS burdens in FGT tissues. a)**
386 Schematic of systemic neutrophil depletion in mice during vaginal colonization. Mice were treated twice with
387 anti-Ly6G or isotype control IgG2a (days -1 and 2) through intraperitoneal injection during vaginal colonization
388 to systemically deplete neutrophils. Mice were colonized with GBS intravaginally on day 0 following β -
389 estradiol injection at day -1 and were euthanized on day 4 for tissue harvest to enumerate CFU in FGT
390 tissues. Recovered CFU counts from the **b, e**) vaginal **c, f**) cervical, and **d, g**) uterine tissue of CJB111 (**b-d**)
391 or COH1-colonized mice (**e-g**). Each dot represents one mouse with $n = 10$ and 13 /group in CJB111 and
392 COH1 experiments, respectively. The bars in these plots show the median and statistics represent the Mann
393 Whitney U test.

394

395 **Figure 2. Total immune cells and neutrophils are not significantly altered over a time-course of GBS**
396 **vaginal colonization.** Line graphs depict **a)** CD45⁺ immune cells as a proportion of single cells and **b)**
397 neutrophils (as a proportion of single cells) or **c)** as a proportion of CD45⁺ immune cells over a time-course
398 of GBS colonization at days 1, 4, 7, 14, and 28. Yellow lines indicate PBS mock-colonized mice and orange
399 lines indicate GBS-colonized mice. Each data point represents the mean and error bars indicate standard
400 error of the mean. The data represents a total of n = 6-8 per timepoint and is combined across 2-3
401 independent experiments at each timepoint. Statistics represent two-way ANOVA with Šídák's multiple
402 comparisons test.

403

404 **Figure 3. FGT $\gamma\delta$ T cells are a primary source of IL-17 production.** **a)** Intracellular IL-17 production
405 measured following five-hour FGT cell stimulation with PMA/ionomycin. IL-17⁺ gate drawn based on
406 fluorescence minus one control. **b)** Representative contour plot of IL-17⁺ cells from stimulated pooled FGT
407 single cell suspensions indicate that this population is comprised primarily by $\gamma\delta$ T cells. Percentages are
408 quantified in **c)**, in which each dot represents one mouse (n = 4, across three independent experiments).
409 Bars in these plots show the median, and statistics represent the Mann Whitney U test. **d)** Percentages of
410 V γ 6⁺ cells of IL-17⁺ $\gamma\delta$ T cells indicate that this $\gamma\delta$ T cell subset is the primary IL-17 producer in the FGT.
411 Each dot represents one mouse (n = 2) and bars indicate the median.

412

413 **Figure 4. Loss of V γ 4/6⁺ $\gamma\delta$ T cells results in increased GBS burdens in female genital tract tissues.**
414 **a)** Percent colonization curves of WT C57BL/6J or V γ 4/6^{-/-} female mice vaginally inoculated with CJB111
415 GBS. Statistics reflect the Log rank (Mantel-Cox) test. Recovered CFU counts from the **b)** vaginal **c)** cervical,
416 and **d)** uterine tissue of colonized mice euthanized at day 47 post-inoculation. Each dot represents one
417 mouse, bars in these plots show the median, and statistics represent the Mann Whitney U test. All graphs
418 represent the combination of two independent experiments (n = 23 C57BL/6J, n = 29 V γ 4/6^{-/-} total mice).

419

420 **References**








- 421 1. Russell NJ, Seale AC, O'Sullivan C, Le Doare K, Heath PT, Lawn JE, et al. Risk of Early-Onset
422 Neonatal Group B Streptococcal Disease With Maternal Colonization Worldwide: Systematic
423 Review and Meta-analyses. *Clin Infect Dis*. 2017 Nov 6;65(suppl_2):S152-S59.
- 424 2. Navarro-Torne A, Curcio D, Moisi JC, Jodar L. Burden of invasive group B Streptococcus disease in
425 non-pregnant adults: A systematic review and meta-analysis. *PLoS One*. 2021;16(9):e0258030.










- 426 3. Anderson BL, Simhan HN, Simons KM, Wiesenfeld HC. Untreated asymptomatic group B
427 streptococcal bacteriuria early in pregnancy and chorioamnionitis at delivery. *Am J Obstet Gynecol*.
428 2007 Jun;196(6):524 e1-5.
- 429 4. Prevention of Group B Streptococcal Early-Onset Disease in Newborns: ACOG Committee Opinion,
430 Number 797. *Obstet Gynecol*. 2020 Feb;135(2):e51-e72.
- 431 5. Melin P. Neonatal group B streptococcal disease: from pathogenesis to preventive strategies. *Clin*
432 *Microbiol Infect*. 2011 Sep;17(9):1294-303.
- 433 6. Schrag SJ, Zywicki S, Farley MM, Reingold AL, Harrison LH, Lefkowitz LB, et al. Group B
434 streptococcal disease in the era of intrapartum antibiotic prophylaxis. *N Engl J Med*. 2000 Jan
435 6;342(1):15-20.
- 436 7. Phares CR, Lynfield R, Farley MM, Mohle-Boetani J, Harrison LH, Petit S, et al. Epidemiology of
437 invasive group B streptococcal disease in the United States, 1999-2005. *JAMA*. 2008 May
438 7;299(17):2056-65.
- 439 8. Verani JR, McGee L, Schrag SJ, Division of Bacterial Diseases NCfl, Respiratory Diseases CfDC,
440 Prevention. Prevention of perinatal group B streptococcal disease--revised guidelines from CDC,
441 2010. *MMWR Recomm Rep*. 2010 Nov 19;59(RR-10):1-36.
- 442 9. Quayle AJ. The innate and early immune response to pathogen challenge in the female genital tract
443 and the pivotal role of epithelial cells. *J Reprod Immunol*. 2002 Oct-Nov;57(1-2):61-79.
- 444 10. Plesniarski A, Siddik AB, Su RC. The Microbiome as a Key Regulator of Female Genital Tract
445 Barrier Function. *Front Cell Infect Microbiol*. 2021;11:790627.
- 446 11. Hickey DK, Patel MV, Fahey JV, Wira CR. Innate and adaptive immunity at mucosal surfaces of the
447 female reproductive tract: stratification and integration of immune protection against the
448 transmission of sexually transmitted infections. *J Reprod Immunol*. 2011 Mar;88(2):185-94.
- 449 12. Sheldon IM, Owens SE, Turner ML. Innate immunity and the sensing of infection, damage and
450 danger in the female genital tract. *J Reprod Immunol*. 2017 Feb;119:67-73.
- 451 13. Sheen TR, Jimenez A, Wang NY, Banerjee A, van Sorge NM, Doran KS. Serine-rich repeat proteins
452 and pili promote *Streptococcus agalactiae* colonization of the vaginal tract. *J Bacteriol*. 2011
453 Dec;193(24):6834-42.
- 454 14. Wang NY, Patras KA, Seo HS, Cavaco CK, Rosler B, Neely MN, et al. Group B streptococcal
455 serine-rich repeat proteins promote interaction with fibrinogen and vaginal colonization. *J Infect Dis*.
456 2014 Sep 15;210(6):982-91.
- 457 15. Manzer HS, Nguyen DT, Park JY, Park N, Seo KS, Thornton JA, et al. The Group B Streptococcal
458 Adhesin BspC Interacts with Host Cytokeratin 19 To Promote Colonization of the Female
459 Reproductive Tract. *mBio*. 2022 Oct 26;13(5):e0178122.
- 460 16. Patras KA, Wang NY, Fletcher EM, Cavaco CK, Jimenez A, Garg M, et al. Group B *Streptococcus*
461 *CovR* regulation modulates host immune signalling pathways to promote vaginal colonization. *Cell*
462 *Microbiol*. 2013 Jul;15(7):1154-67.
- 463 17. Carey AJ, Tan CK, Mirza S, Irving-Rodgers H, Webb RI, Lam A, et al. Infection and cellular defense
464 dynamics in a novel 17beta-estradiol murine model of chronic human group B streptococcus genital
465 tract colonization reveal a role for hemolysin in persistence and neutrophil accumulation. *J Immunol*.
466 2014 Feb 15;192(4):1718-31.
- 467 18. Randis TM, Gelber SE, Hooven TA, Abellar RG, Akabas LH, Lewis EL, et al. Group B
468 *Streptococcus* beta-hemolysin/cytolysin breaches maternal-fetal barriers to cause preterm birth and
469 intrauterine fetal demise in vivo. *J Infect Dis*. 2014 Jul 15;210(2):265-73.
- 470 19. Vornhagen J, Quach P, Boldenow E, Merillat S, Whidbey C, Ngo LY, et al. Bacterial Hyaluronidase
471 Promotes Ascending GBS Infection and Preterm Birth. *mBio*. 2016 Jun 28;7(3).
- 472 20. Dammann AN, Chamby AB, Gonzalez FJ, Sharp ME, Flores K, Shahi I, et al. Group B
473 *Streptococcus* Capsular Serotype Alters Vaginal Colonization Fitness. *J Infect Dis*. 2022 Jun
474 1;225(11):1896-904.
- 475 21. Spencer BL, Doran KS. Evolving understanding of the type VII secretion system in Gram-positive
476 bacteria. *PLoS Pathog*. 2022 Jul;18(7):e1010680.
- 477 22. Spencer BL, Job AM, Robertson CM, Hameed ZA, Serchejian C, Wiafe-Kwakye CS, et al.
478 Heterogeneity of the group B streptococcal type VII secretion system and influence on colonization
479 of the female genital tract. *Molecular Microbiology*. 2023;120(2):258-75.




- 480 23. Patras KA, Rosler B, Thoman ML, Doran KS. Characterization of host immunity during persistent
481 vaginal colonization by Group B Streptococcus. *Mucosal Immunol.* 2015 Nov;8(6):1339-48.
- 482 24. Sweeney EL, Gardiner S, Tickner J, Trim L, Beagley KW, Carey AJ. Group B Streptococcus
483 serotypes Ia and V induce differential vaginal immune responses that may contribute to long term
484 colonization of the female reproductive tract. *Am J Reprod Immunol.* 2020 Jan;83(1):e13199.
- 485 25. Da Cunha V, Davies MR, Douarre PE, Rosinski-Chupin I, Margarit I, Spinali S, et al. Streptococcus
486 agalactiae clones infecting humans were selected and fixed through the extensive use of
487 tetracycline. *Nat Commun.* 2014 Aug 4;5:4544.
- 488 26. Spencer BL, Chatterjee A, Duerkop BA, Baker CJ, Doran KS. Complete Genome Sequence of
489 Neonatal Clinical Group B Streptococcal Isolate CJB111. *Microbiol Resour Announc.* 2021 Jan
14;10(2).
- 491 27. Moses K, Klein JC, Mann L, Klingberg A, Gunzer M, Brandau S. Survival of residual neutrophils and
492 accelerated myelopoiesis limit the efficacy of antibody-mediated depletion of Ly-6G+ cells in tumor-
493 bearing mice. *J Leukoc Biol.* 2016 Jun;99(6):811-23.
- 494 28. Patras KA, Doran KS. A Murine Model of Group B Streptococcus Vaginal Colonization. *J Vis Exp.*
495 2016 Nov 16(117).
- 496 29. Yu YR, O'Koren EG, Hotten DF, Kan MJ, Kopin D, Nelson ER, et al. A Protocol for the
497 Comprehensive Flow Cytometric Analysis of Immune Cells in Normal and Inflamed Murine Non-
498 Lymphoid Tissues. *PLoS One.* 2016;11(3):e0150606.
- 499 30. Hatano S, Tun X, Noguchi N, Yue D, Yamada H, Sun X, et al. Development of a new monoclonal
500 antibody specific to mouse Vgamma6 chain. *Life Sci Alliance.* 2019 Jun;2(3).
- 501 31. Weaver CT, Elson CO, Fouser LA, Kolls JK. The Th17 pathway and inflammatory diseases of the
502 intestines, lungs, and skin. *Annu Rev Pathol.* 2013 Jan 24;8:477-512.
- 503 32. Mills KH. Induction, function and regulation of IL-17-producing T cells. *Eur J Immunol.* 2008
504 Oct;38(10):2636-49.
- 505 33. Roark CL, Simonian PL, Fontenot AP, Born WK, O'Brien RL. gammadelta T cells: an important
506 source of IL-17. *Curr Opin Immunol.* 2008 Jun;20(3):353-7.
- 507 34. Anipindi VC, Bagri P, Dizzell SE, Jimenez-Saiz R, Jordana M, Snider DP, et al. IL-17 Production by
508 gammadelta(+) T Cells Is Critical for Inducing T(h)17 Responses in the Female Genital Tract and
509 Regulated by Estradiol and Microbiota. *Immunohorizons.* 2019 Jul 17;3(7):317-30.
- 510 35. Sunaga S, Maki K, Komagata Y, Miyazaki J, Ikuta K. Developmentally ordered V-J recombination in
511 mouse T cell receptor gamma locus is not perturbed by targeted deletion of the Vgamma4 gene. *J*
512 *Immunol.* 1997 May 1;158(9):4223-8.
- 513 36. Phalke SP, Huang Y, Rubtsova K, Getahun A, Sun D, Reinhardt RL, et al. gammadelta T cells
514 shape memory-phenotype alpha beta T cell populations in non-immunized mice. *PLoS One.*
515 2019;14(6):e0218827.
- 516 37. Gendrin C, Shubin NJ, Boldenow E, Merillat S, Clauson M, Power D, et al. Mast cell chymase
517 decreases the severity of group B *Streptococcus* infections. *J Allergy Clin Immunol.* 2017 Sep 12.
- 518 38. Baker JA, Lewis EL, Byland LM, Bonakdar M, Randis TM, Ratner AJ. Mucosal vaccination promotes
519 clearance of Streptococcus agalactiae vaginal colonization. *Vaccine.* 2017 Mar 1;35(9):1273-80.
- 520 39. Huang Y, Getahun A, Heiser RA, Detanico TO, Aviszus K, Kirchenbaum GA, et al. gammadelta T
521 Cells Shape Preimmune Peripheral B Cell Populations. *J Immunol.* 2016 Jan 1;196(1):217-31.
- 522 40. Kline KA, Schwartz DJ, Lewis WG, Hultgren SJ, Lewis AL. Immune activation and suppression by
523 group B streptococcus in a murine model of urinary tract infection. *Infect Immun.* 2011
524 Sep;79(9):3588-95.
- 525 41. Mercado-Evans V, Mejia ME, Zulk JJ, Ottinger S, Hameed ZA, Serchejian C, et al. Gestational
526 diabetes augments group B Streptococcus infection by disrupting maternal immunity and the
527 vaginal microbiota. *Nat Commun.* 2024 Feb 3;15(1):1035.
- 528 42. Hansen SM, Uldbjerg N, Kilian M, Sorensen UB. Dynamics of Streptococcus agalactiae colonization
529 in women during and after pregnancy and in their infants. *J Clin Microbiol.* 2004 Jan;42(1):83-9.
- 530 43. Manning SD, Schaeffer KE, Springman AC, Lehotzky E, Lewis MA, Ouellette LM, et al. Genetic
531 diversity and antimicrobial resistance in group B streptococcus colonizing young, nonpregnant
532 women. *Clin Infect Dis.* 2008 Aug 1;47(3):388-90.

- 533 44. Cheng PJ, Chueh HY, Liu CM, Hsu JJ, Hsieh TT, Soong YK. Risk factors for recurrence of group B
534 streptococcus colonization in a subsequent pregnancy. *Obstet Gynecol.* 2008 Mar;111(3):704-9.
- 535 45. Kim CJ, Romero R, Chaemsaihong P, Chaiyasit N, Yoon BH, Kim YM. Acute chorioamnionitis and
536 funisitis: definition, pathologic features, and clinical significance. *Am J Obstet Gynecol.* 2015
537 Oct;213(4 Suppl):S29-52.
- 538 46. Kothary V, Doster RS, Rogers LM, Kirk LA, Boyd KL, Romano-Keeler J, et al. Group B
539 Streptococcus Induces Neutrophil Recruitment to Gestational Tissues and Elaboration of
540 Extracellular Traps and Nutritional Immunity. *Front Cell Infect Microbiol.* 2017;7:19.
- 541 47. Rogers LM, Anders AP, Doster RS, Gill EA, Gnecco JS, Holley JM, et al. Decidual stromal cell-
542 derived PGE(2) regulates macrophage responses to microbial threat. *Am J Reprod Immunol.* 2018
543 Oct;80(4):e13032.
- 544 48. Doster RS, Sutton JA, Rogers LM, Aronoff DM, Gaddy JA. Streptococcus agalactiae Induces
545 Placental Macrophages To Release Extracellular Traps Loaded with Tissue Remodeling Enzymes
546 via an Oxidative Burst-Dependent Mechanism. *mBio.* 2018 Nov 20;9(6).
- 547 49. Boldenow E, Gendrin C, Ngo L, Bierle C, Vornhagen J, Coleman M, et al. Group B Streptococcus
548 circumvents neutrophils and neutrophil extracellular traps during amniotic cavity invasion and
549 preterm labor. *Sci Immunol.* 2016 Oct;1(4).
- 550 50. Korir ML, Doster RS, Lu J, Guevara MA, Spicer SK, Moore RE, et al. Streptococcus agalactiae
551 cadD alleviates metal stress and promotes intracellular survival in macrophages and ascending
552 infection during pregnancy. *Nat Commun.* 2022 Sep 14;13(1):5392.
- 553 51. Kuperwaser F, Avital G, Vaz MJ, Noble KN, Dammann AN, Randis TM, et al. Host inflammatory
554 dynamics reveal placental immune modulation by Group B Streptococcus during pregnancy. *Mol
555 Syst Biol.* 2023 Mar 9;19(3):e11021.
- 556 52. Liu JZ, Pezeshki M, Raffatellu M. Th17 cytokines and host-pathogen interactions at the mucosa:
557 dichotomies of help and harm. *Cytokine.* 2009 Oct-Nov;48(1-2):156-60.
- 558 53. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. *Annu Rev Immunol.* 2009;27:485-
559 517.
- 560 54. O'Brien RL, Roark CL, Born WK. IL-17-producing gammadelta T cells. *Eur J Immunol.* 2009
561 Mar;39(3):662-6.
- 562 55. Srenathan U, Steel K, Taams LS. IL-17+ CD8+ T cells: Differentiation, phenotype and role in
563 inflammatory disease. *Immunol Lett.* 2016 Oct;178:20-6.
- 564 56. Gibbs A, Leeansyah E, Introini A, Paquin-Proulx D, Hasselrot K, Andersson E, et al. MAIT cells
565 reside in the female genital mucosa and are biased towards IL-17 and IL-22 production in response
566 to bacterial stimulation. *Mucosal Immunol.* 2017 Jan;10(1):35-45.
- 567 57. Michel ML, Mendes-da-Cruz D, Keller AC, Lochner M, Schneider E, Dy M, et al. Critical role of
568 ROR-gammat in a new thymic pathway leading to IL-17-producing invariant NKT cell differentiation.
569 *Proc Natl Acad Sci U S A.* 2008 Dec 16;105(50):19845-50.
- 570 58. Rachitskaya AV, Hansen AM, Horai R, Li Z, Villasmil R, Luger D, et al. Cutting edge: NKT cells
571 constitutively express IL-23 receptor and RORgammat and rapidly produce IL-17 upon receptor
572 ligation in an IL-6-independent fashion. *J Immunol.* 2008 Apr 15;180(8):5167-71.
- 573 59. Tuttle KD, Krovi SH, Zhang J, Bedel R, Harmacek L, Peterson LK, et al. TCR signal strength
574 controls thymic differentiation of iNKT cell subsets. *Nat Commun.* 2018 Jul 9;9(1):2650.
- 575 60. Spits H, Artis D, Colonna M, Diefenbach A, Di Santo JP, Eberl G, et al. Innate lymphoid cells--a
576 proposal for uniform nomenclature. *Nat Rev Immunol.* 2013 Feb;13(2):145-9.
- 577 61. Song C, Luo L, Lei Z, Li B, Liang Z, Liu G, et al. IL-17-producing alveolar macrophages mediate
578 allergic lung inflammation related to asthma. *J Immunol.* 2008 Nov 1;181(9):6117-24.
- 579 62. Werner JL, Gessner MA, Lilly LM, Nelson MP, Metz AE, Horn D, et al. Neutrophils produce
580 interleukin 17A (IL-17A) in a dectin-1- and IL-23-dependent manner during invasive fungal infection.
581 *Infect Immun.* 2011 Oct;79(10):3966-77.
- 582 63. Stark MA, Huo Y, Burcin TL, Morris MA, Olson TS, Ley K. Phagocytosis of apoptotic neutrophils
583 regulates granulopoiesis via IL-23 and IL-17. *Immunity.* 2005 Mar;22(3):285-94.
- 584 64. Romani L, Fallarino F, De Luca A, Montagnoli C, D'Angelo C, Zelante T, et al. Defective tryptophan
585 catabolism underlies inflammation in mouse chronic granulomatous disease. *Nature.* 2008 Jan
586 10;451(7175):211-5.

- 587 65. Kurioka A, van Wilgenburg B, Javan RR, Hoyle R, van Tonder AJ, Harrold CL, et al. Diverse
588 *Streptococcus pneumoniae* Strains Drive a Mucosal-Associated Invariant T-Cell Response Through
589 Major Histocompatibility Complex class I-Related Molecule-Dependent and Cytokine-Driven
590 Pathways. *J Infect Dis*. 2018 Mar 5;217(6):988-99.
- 591 66. Kinjo Y, Illarionov P, Vela JL, Pei B, Girardi E, Li X, et al. Invariant natural killer T cells recognize
592 glycolipids from pathogenic Gram-positive bacteria. *Nat Immunol*. 2011 Sep 4;12(10):966-74.
- 593 67. Furuta A, Coleman M, Casares R, Seepersaud R, Orvis A, Brokaw A, et al. CD1 and iNKT cells
594 mediate immune responses against the GBS hemolytic lipid toxin induced by a non-toxic analog.
595 *PLoS Pathog*. 2023 Jun;19(6):e1011490.
- 596 68. Okumura CY, Nizet V. Subterfuge and sabotage: evasion of host innate defenses by invasive gram-
597 positive bacterial pathogens. *Annu Rev Microbiol*. 2014;68:439-58.
- 598 69. Korir ML, Manning SD, Davies HD. Intrinsic Maturation Neonatal Immune Deficiencies and
599 Susceptibility to Group B *Streptococcus* Infection. *Clin Microbiol Rev*. 2017 Oct;30(4):973-89.
- 600 70. Liu GY, Doran KS, Lawrence T, Turkson N, Puliti M, Tissi L, et al. Sword and shield: linked group B
601 streptococcal beta-hemolysin/cytolysin and carotenoid pigment function to subvert host phagocyte
602 defense. *Proc Natl Acad Sci U S A*. 2004 Oct 05;101(40):14491-6.
- 603 71. Whidbey C, Vornhagen J, Gendrin C, Boldenow E, Samson JM, Doering K, et al. A streptococcal
604 lipid toxin induces membrane permeabilization and pyroptosis leading to fetal injury. *EMBO Mol
605 Med*. 2015 Apr;7(4):488-505.
- 606 72. Armistead B, Herrero-Foncubierta P, Coleman M, Quach P, Whidbey C, Justicia J, et al. Lipid
607 analogs reveal features critical for hemolysis and diminish granadaene mediated Group B
608 *Streptococcus* infection. *Nat Commun*. 2020 Mar 20;11(1):1502.
- 609

a**b****c****d****e****f****g**

a**CD45+**
(% of Single)**b****Neutrophil**
(% of Single)**c****Neutrophil**
(% of CD45+)

a**Stimulated****b** IL-17⁺ cells**c****d**